Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. President and COO Elizabeth Bhatt exercised stock options and sold shares in a planned transaction. She exercised options for 4,000 shares of Common Stock at an exercise price of $6.81 per share, then sold the same 4,000 shares in open-market trades at weighted average prices between about $23.33 and $25.91. The sales were made under a pre-arranged Rule 10b5-1 sales plan adopted on October 20, 2025. Following these transactions, she directly owned 174,535 shares of Common Stock.
Septerna, Inc. has begun a Phase 1 clinical trial of SEP-479, an oral small molecule PTH1R agonist being developed for hypoparathyroidism. The randomized, placebo-controlled study in healthy adults includes single-ascending and multiple-ascending dose cohorts, with enrollment of up to approximately 150 participants in Australia.
The trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics, including effects on endogenous parathyroid hormone and serum calcium, and includes a crossover food-effect study. Septerna anticipates reporting SAD/MAD data in late 2026 or early 2027. SEP-479 aims to offer once-daily oral PTH replacement based on supportive preclinical data.
Septerna, Inc. files a Form S-3ASR and launches an at-the-market equity program registering up to $150,000,000 of common stock. The company may sell shares from time to time under a sales agreement with BofA Securities, Inc. dated March 10, 2026, including sales directly to the agent as principal.
Septerna describes its business as a clinical-stage biotechnology company focused on GPCR oral small-molecule drug discovery using its Native Complex Platform®. The prospectus states shares outstanding were 44,806,272 as of December 31, 2025.
Septerna, Inc. filed its Annual Report describing a clinical‑stage GPCR-focused biotech with multiple oral small‑molecule programs and a new large collaboration. The company highlights lead candidates SEP‑479 for hypoparathyroidism and SEP‑631 for chronic spontaneous urticaria, plus an early TSHR program for Graves’ disease and thyroid eye disease.
Septerna reports a global collaboration with Novo Nordisk to discover oral metabolic drugs across five GPCR targets, including GLP‑1, GIP and glucagon receptors, with a $195.0 million upfront payment and potential per‑program milestones of about $498.0 million plus tiered royalties. As of March 2, 2026, it had 44,906,374 common shares outstanding and non‑affiliate market value of about $363.3 million as of June 30, 2025.
The filing emphasizes that Septerna has a limited operating history, expects significant ongoing losses, and will require substantial additional funding. It details extensive clinical, regulatory, manufacturing and competitive risks typical of early‑stage biotech, while positioning its Native Complex Platform® as the core engine for future pipeline growth.
Septerna, Inc. reported strong fourth quarter and full year 2025 results alongside major pipeline progress. Revenue rose to $24.1 million in the fourth quarter of 2025 and $46.0 million for the full year, up sharply from $0.2 million and $1.1 million in 2024, primarily reflecting collaboration work and amortization of a Novo Nordisk upfront payment.
The company recorded a net loss of $10.7 million for the quarter and $48.9 million for 2025, narrowing from $20.7 million and $71.8 million in 2024, as higher revenue partially offset increased R&D and G&A expenses. Cash, cash equivalents, and marketable securities were $548.7 million as of December 31, 2025, and the cash runway is expected to fund operations at least into 2029.
Clinically, Septerna reported compelling Phase 1 data for SEP-631 in mast cell diseases, supporting Phase 2b development in chronic spontaneous urticaria in the second half of 2026, and is advancing SEP-479 toward a Phase 1 trial in the first half of 2026, while continuing progress on its TSHR NAM and discovery programs.
Septerna, Inc. Chief People Officer Samira Shaikhly exercised several stock options on March 2, 2026, converting 53,714, 11,638, and 5,101 option shares into common stock at exercise prices of $1.55 and $2.76 per share. She then sold a total of 70,453 common shares in open-market transactions at weighted-average prices of $27.5052 and $28.1383, under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025. After these trades, she directly held 793 Septerna common shares, a balance that includes shares acquired through the company’s 2024 Employee Stock Purchase Plan.
Septerna, Inc. reported positive Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2 being developed for mast cell-driven diseases. In healthy volunteers, SEP-631 was well tolerated across single and multiple ascending doses, with an adverse event profile comparable to placebo.
The drug showed dose-proportional pharmacokinetics with an approximate 24-hour half-life, supporting once-daily oral dosing and no meaningful food effect. Using an icatibant-induced skin wheal test, SEP-631 produced robust, dose-dependent suppression of wheal formation, with complete inhibition at doses as low as 10 mg once daily, providing clinical proof-of-mechanism for MRGPRX2 pathway blockade.
Based on these data, Septerna plans to start a randomized, double-blind, placebo-controlled Phase 2b trial of SEP-631 in adults with moderate-to-severe chronic spontaneous urticaria in the second half of 2026, and to follow with an open-label study in chronic inducible urticaria. The company is also evaluating SEP-631 in additional mast cell-driven indications, including atopic dermatitis, interstitial cystitis, migraine and asthma.
Septerna, Inc. President and COO Elizabeth Bhatt reported option exercises and stock sales. On February 18, 2026, she exercised stock options for 4,000 shares at an exercise price of $6.81 per share and received 4,000 shares of common stock.
She then sold 2,200 shares of common stock at a weighted average price of $28.4594 per share and 1,800 shares at a weighted average price of $29.5831 per share in open‑market transactions under a Rule 10b5‑1 sales plan adopted on October 20, 2025. After these trades, she directly owned 174,209 shares of common stock and held 88,911 stock options.